All In Biotech

Drug Trial Radar · NCT03031210

Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.

Treatment of Non-severe Community Acquired Pneumonia With Twice Daily Compared to Thrice Daily Regimen- A Non-inferiority Pragmatic Randomized-controlled Trial.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,370 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,370

Planned (sponsor's estimate)

Start

Jun 11, 2017

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
St. Justine's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 months, up to 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).

Conditions

  • Community-acquired Pneumonia

Interventions

  • AmoxicillinDrug

    (90 mg/kg/day) twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical failure within 10 days of enrolmentTime frame: Day 10 (after enrolment)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU Sainte-Justine

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.